ReviewCancers2023
Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07625189 (Prospective Observational Registry of EUS-Guided Ablation), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Observational Registry of EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions
Who cites it
30 citing papers in PubMed, 38 citations in OpenAlex.
- Preliminary Application of TROP2-Targeted Peptide Screening for Real-Time Intraoperative Navigation in Pancreatic Cancer.Chemical & biomedical imaging · 2026Article
- Factors Associated with Improved Survival for Stage I and II Pancreatic Adenocarcinoma Utilizing the National Cancer Database.Journal of gastrointestinal cancer · 2026Article
- Inpatient Outcomes of Pancreatic Cancer Surgery in Patients with Coronary Artery Disease.Cancers · 2026Article
- Non-ablative focused ultrasound induces an adaptive immune response to suppress pancreatic cancer: a preclinical study.Ultrasonography (Seoul, Korea) · 2026Article
- Prognostic impact of pathologically confirmed venous infiltration during upfront pancreatectomy: multicenter survival analysis.Langenbeck's archives of surgery · 2026Article
- Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- VISTA drives pancreatic tumor progression through modulation of the tumor-associated macrophage polarity.Nature communications · 2026Article
- Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation.Frontiers in immunology · 2026Review
- Diagnosis and Surgical Management for Advanced Pancreatic Cancer Requiring Vascular Resection.Diagnostics (Basel, Switzerland) · 2025Review
- Neoadjuvant SBRT and intraoperative electron radiotherapy in pancreatic cancer resection.Journal of cancer research and clinical oncology · 2025Article
- Immediate Postoperative AbnobaVISCUMYonsei medical journal · 2025Article
- Article
- Advances in MRI in the Evaluation of Chronic Pancreatitis and the Less Common Forms of Pancreatitis.Advances in clinical radiology · 2025Article
- Treatment and Survival for Unresectable Pancreatic Adenocarcinoma in Queensland, Australia, 2018-2022.Cancer medicine · 2025Article
- Review
- Article
- Article
- Survival Outcomes in Nonmetastatic pT4 Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis Comparing Neoadjuvant Therapy and Upfront Surgery with Propensity Score Matching.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Pancreatic Cancer Patients Supportive Care Needs: A Qualitative Analysis.Psycho-oncology · 2025Article
- Interaction of Avapritinib with Congo Red in Pancreatic Cancer Cells: Molecular Modeling and Biophysical Studies.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radical resection is the only curative treatment for pancreatic cancer. However, only up to 20% of patients are considered eligible for surgical resection at the time of diagnosis. Although upfront surgery followed by adjuvant chemotherapy has become the gold standard of treatment for resectable pancreatic cancer there are numerous ongoing trials aiming to compare the clinical outcomes of various surgical strategies (e.g., upfront surgery or neoadjuvant treatment with subsequent resection). Neoadjuvant treatment followed by surgery is considered the best approach in borderline resectable pancreatic tumors. Individuals with locally advanced disease are now candidates for palliative chemo- or chemoradiotherapy; however, some patients may become eligible for resection during the course of such treatment. When metastases are found, the cancer is qualified as unresectable. It is possible to perform radical pancreatic resection with metastasectomy in selected cases of oligometastatic disease. The role of multi-visceral resection, which involves reconstruction of major mesenteric veins, is well known. Nonetheless, there are some controversies in terms of arterial resection and reconstruction. Researchers are also trying to introduce personalized treatments. The careful, preliminary selection of patients eligible for surgery and other therapies should be based on tumor biology, among other factors. Such selection may play a key role in improving survival rates in patients with pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.